Dihydrotachysterol (DHT) is a synthetic vitamin D analog activated in the liver that does not require renal hydroxylation like vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). DHT has a rapid onset of action (2 hours), a shorter half-life, and a greater effect on mineralization of bone salts than does vitamin D
Canagliflozin (INN, trade name Invokana) is a drug for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney.
Bupropion (Wellbutrin, Zyban, Voxra, Budeprion, Prexaton, Elontril or Aplenzin ) is an atypical antidepressant and smoking cessation aid. It is a norepinephrine-dopamine reuptake inhibitor. It is also a nicotinic acetylcholine receptor antagonist. Treatment of Hypoactive Sexual Desire Disorder (HSDD) in women.
Urokinase (Abbokinase), also called urokinase-type plasminogen activator (uPA), is a serine protease. Urokinase was originally isolated from human urine, but it is also found in the blood and extracellular matrix. It's substrate is plasminogen, which is an inactive zymogen form of the serine protease plasmin. Activation of plasmin triggers a proteolysis cascade that, depending on the physiological environment, participates in thrombolysis or extracellular matrix degradation.
Thioamides (or rarely thionamides) are major drugs for treatment of thyrotoxicosis and hyperthyroidism. Some alternative antithyroid drugs are iodide, glucocorticoids and anion inhibitors (perchlorate (ClO4–), pertechnetate (TcO4–), and thiocyanate (SCN–). Thioamides are relatively simple molecules which contain a sulfhydryl group and a thiourea moiety within a heterocyclic structure. Most common thionamides are: 1. propylthiouracil 2.methimazole 3.carbimazole
Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (Europe) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance. Telbivudine is a synthetic thymidine nucleoside analogue; it is the L-isomer of thymidine. It is taken once daily.